SecBot SecBot
SC 13G ·Filed Nov 9, 2026

IMCR

Immunocore Holdings plc
NEUTRAL
Impact 4/10
Horizonweeks Processed7d 7h ago SEC0000919574-26-007502
Passive investor 5%+ stake
Actionable Insight • Neutral

Point72's new 5.2% passive stake signals conviction in Immunocore's pipeline, particularly the Phase 3 TEBE-AM trial with topline OS data expected Q2 2027. Monitor for any future 13D conversion or additional stake increases, though the filing certifies passive intent.

DirectionNeutral
Confidencehigh
Horizonweeks

KIMMTRAK

▲ Bullish Named in this SC 13G
Impact
Phase
Approved
Time to market
Already approved and commercialized (since January 2022). Label expansion into cutaneous melanoma depends on Phase 3 TEBE-AM data expected by end of 2026; if positive, an sBLA submission would follow, with potential approval in 2027-2028.
Next catalyst
None dated

What to watchThe key near-term catalyst is the Phase 3 TEBE-AM topline readout for KIMMTRAK in cutaneous melanoma, expected by end of 2026 (~4 months away). A positive result could double the addressable market; a negative readout would be a major setback. With ~16.4% of shares short and ~18.8 days to cover, a positive readout could trigger significant short-covering upside. Watch for enrollment completion announcements and any data updates at medical meetings in H2 2026.

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+1
Entry
$32.38
T+0 close · Nov 9, 2026 · via day close
Latest settled
−2.25%
T+1 · $31.65 · next T+5 in 6h
Vs SPY
−3.57%
α at T+1
Latest observation
−9.25%
T+4 · FF3 residual α
  1. T+0 · Nov 10 $32.38entry
  2. T+1 · 6d ago −2.25%α −3.57% · $31.65
  3. T+4 · todayOpen
  4. T+5 · in 6h Pending
  5. T+20 · in 22d Pending
  6. T+60 · in 3mo Pending

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Point72 Asset Management, L.P. (Steven Cohen's firm) filed a new Schedule 13G disclosing a 5.2% passive stake in Immunocore Holdings plc, representing 2,720,043 ordinary shares (including 501,604 shares issuable upon conversion of convertible notes) as of November 6, 2026. This is a new 5%+ disclosure from a prominent hedge fund, filed three days after Immunocore's Q3 earnings report showing flat KIMMTRAK revenue and a widened net loss.

Key Financial Metrics

Stake
5.2%
Stake Value
$78.0M
Investor
Point72 Asset Management, L.P.
Investor Type
hedge fund

Key Facts

  • Point72 Asset Management disclosed a 5.2% passive stake in Immunocore Holdings plc as of November 6, 2026
  • Stake consists of 2,720,043 ordinary shares, including 501,604 shares issuable upon conversion of convertible notes
  • Filing is a new Schedule 13G (not an amendment), indicating Point72 crossed the 5% threshold
  • Point72 certifies passive intent under Rule 13d-1(c), with no activist purpose
  • Filing comes 3 days after Immunocore's Q3 2026 earnings (Nov 6), which showed KIMMTRAK revenue of $102.2M (down 1.4% YoY) and a net loss of $14.2M

Financial Impact

5.2% stake valued at approximately $78M based on $1.5B market cap

ownershipdilution

Risk Factors

  • Point72 could convert to an activist 13D filing if it seeks changes, though no such intent is stated
  • The stake includes 501,604 shares issuable upon convertible note conversion, adding potential dilution

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
74% bullish (19 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
SC 13G Filing (Primary)0000919574-26-007502
Document: 0000919574-26-007502-index-headers.html0000919574-26-007502
Document: 0000919574-26-007502-index.html0000919574-26-007502
Document: 0000919574-26-007502.txt0000919574-26-007502

Track record

14 reports on IMCR

Performance horizon

2 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +28.39% at T+60 after the May 31, 2026 report. 4 of 5 went positive at some point.

Filters
  1. Nov 9, 20267d ago SC 13G Neutral 4/10 Viewing Entry $32.38 Now $28.88 −10.81% settles Feb 8
  2. Nov 6, 202610d ago Press Release Neutral 4/10 Entry $30.99 Now $28.88 −6.81% settles Feb 4
  3. Nov 6, 202610d ago 8-K Neutral 4/10 No price data
  4. Nov 6, 202610d ago Press Release Bearish 5/10 Entry $30.99 Now $28.88 +6.81% settles Feb 4
  5. Oct 29, 202618d ago Press Release Neutral 3/10 Entry $31.27 Now $28.88 −7.64% settles Jan 27
  6. Oct 15, 20264w ago Press Release Neutral 4/10 Entry $29.48 Now $28.88 −2.04% settles Jan 12
  7. Oct 7, 20265w ago SC 13G/A Neutral 3/10 Entry $29.41 Now $28.88 −1.80% settles Jan 4
  8. Sep 14, 20269w ago 8-K Bullish 6/10 Entry $32.46 Now $28.88 −11.03% settles Dec 8
  9. Aug 6, 202614w ago 8-K Mixed 5/10 Entry $34.50 to $30.49 Now $28.88 −16.29% ▼ −11.62% −9.95% vs SPY
  10. May 31, 202624w ago Press Release Bullish 6/10 Entry $29.13 to $37.40 Now $28.88 −0.86% ▲ +28.39% +27.16% vs SPY
Showing 10 of 14

US Market Status

Market Closed · Opens in 8h 17m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 9, 2026